Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Canaccord Genuity raised its price target on Artivion Inc. (NYSE:AORT) to $41.00 from $35.00 on Friday, maintaining a Buy rating following the company’s strong second-quarter performance. The medical device company, with a market capitalization of $1.54 billion, is currently trading near its 52-week high of $33.39, though InvestingPro analysis suggests the stock may be overvalued at current levels.
Artivion reported Q2 revenue of $113.0 million, representing 15.3% year-over-year growth and exceeding both Canaccord’s estimate of $108.7 million and the consensus forecast of $108.0 million. The company’s adjusted EBITDA reached $24.8 million, surpassing Canaccord’s projection of $23.7 million and the consensus estimate of $21.1 million. The company maintains strong financial health with a robust gross margin of 63.94% and excellent liquidity, as evidenced by a current ratio of 5.53.
The outperformance was primarily driven by strength in Artivion’s Aortic Stent Graft business, particularly the AMDS product, and robust sales in the U.S. On-X business. Canaccord noted that Artivion has successfully capitalized on cross-selling opportunities with On-X as it continues to launch AMDS into accounts under the Humanitarian Device Exemption (HDE) and train physicians.
Artivion has raised its fiscal year 2025 guidance and now projects constant currency growth of 12%-14% year-over-year, reflecting increased confidence in its business trajectory.
Canaccord believes Q2 marks just the beginning for Artivion, citing the company’s deep pipeline of PMA (Premarket Approval) products as a catalyst for future growth.
In other recent news, Artivion Inc. reported strong financial results for the second quarter of 2025. The company achieved a revenue of $113 million, which marked a 14% increase compared to the previous year. This performance surpassed both Oppenheimer’s and consensus estimates of $109 million and $108 million, respectively. Additionally, Artivion posted an earnings per share (EPS) of $0.24, significantly outperforming the anticipated loss of $0.0033. Following these robust results, Oppenheimer adjusted its price target for Artivion, initially raising it from $32 to $40, while maintaining an Outperform rating. This reflects confidence in Artivion’s continued growth and potential. These recent developments highlight the company’s strong market performance and positive outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.